Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life after chemotherapy cycle in breast cancer in Iran

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to compare the differences between the level of whole quality of life and its subscales after receiving two common treatment of breast cancer in women with early stage of breast cancer. A double-blinded cohort study was done in 100 breast cancer patients with node positive that used fluorouracil, doxorubicin, cyclophosphamide (FAC) and docetaxel, doxorubicin and cyclophosphamide (TAC) regimen as adjuvant therapy. Patients were followed for 4 months since the end of chemotherapy. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). Independent t-test analysis was used at the significant level of 0.05 for analyzing the results. The mean of age was 48.49 ± 10.63 in these patients. QoL scores were 64 and 68 in TAC and FAC groups, respectively (P < 0.001). After 4 months, patients in TAC and FAC groups experienced 11.45 and 7.14 units of improvement in QoL scores, respectively (P = 0.02). Although, TAC had a more negative impact on QoL during chemotherapy, it created a higher improvement than FAC during 4 months since the end of treatment. These effects on quality of life should be considered in making decision for providing and financing cancer treatments in Iran.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gordon L, Battistutta D, Scuffham P, Tweeddale M, Newman B. The impact of rehabilitation support services on health related quality of life for women with breast cancer. Breast Cancer Res Treat. 2005;93(3):217–26.

    Article  PubMed  Google Scholar 

  2. Cella D, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology. 1990;5:29–38.

    Google Scholar 

  3. Apolone G, Filibert A, Cifani S, Ruggiate R, Mosconi P. Evaluation of the EORTCQLQ-C30 questionnaire : a comparison with SF-36 health survey in a cohort of Italian long survival cancer patients. Ann Oncol. 1998;9:549–57.

    Article  PubMed  CAS  Google Scholar 

  4. Montazeri M, Vahdaninia A, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an 18 months follow up study. BMC Cancer. 2008;8:330–6.

    Article  PubMed  Google Scholar 

  5. Abachi Zade K, Tabatabai SM, Khayam Zade M, Akbari MS. Comparing different types of cancers in Iran with EMRO and the world. Drug Treat. 2008;66:40–3. (in Persian).

    Google Scholar 

  6. Stewart BW, Paul Kleihues P World cancer report. Lyon, France, International agency research on cancer. 2003.

  7. Disipio T, Hayes S, Newman B, Janda M. Health related quality of life 18 months after breast cancer: comparison with the general population of Queensland, Australia. Support Care Cancer. 2008;16(10):1141–50.

    Article  PubMed  Google Scholar 

  8. Hatam N, Ahmadloo N, Ahmad Kiadaliri A, Bastani P, Askarian M Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) in comparison with FAC (doxorubicin, cyclophosphamide, 5 fluorouracil). Arch Gynecol Obstet. doi: 10.1007/s00404-010-1609-8.

  9. SangGyu L, Young Geon J, Hyun chul Ch, Sung Bae K. Cost-effectiveness analysis of adjuvant therapy for node-positive breast cancer in Korea. Breast Cancer Res Treat. 2009;114(3):589–96.

    Article  Google Scholar 

  10. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.

    Article  PubMed  CAS  Google Scholar 

  11. Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, et al. The European organization for research & treatment of cancer quality of life questionnaire (EORTC QLQ-C30) : translation & validation study of the Iranian version. Support Care Cancer. 1999;7:400–6.

    Article  PubMed  CAS  Google Scholar 

  12. Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, et al. The EORTC breast cancer-specific quality of life questionnaire (EORTC- BR23): translation & validation study of the Iranian version. Qual Life Res. 2000;9(2):177–84.

    Article  PubMed  CAS  Google Scholar 

  13. http://www.eortc.be/home/qol/downloads/f/scmanualQLQ-C30.pdf.

  14. StataCorp. Stata statistical software 10. StataCorp, College Station, TX (Computer program).

  15. Larsson J, Sandelin K, Forsberg C. Health related quality of life and healthcare experiences in breast cancer patients in a study of Swedish women. Cancer Nurs. 2010;33(2):164–70.

    Article  PubMed  Google Scholar 

  16. Elder EE, Brandberg Y, Bjorklund T, Rylander R, Lagergren J, Jurell G. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast. 2005;14(3):201–8.

    Article  PubMed  Google Scholar 

  17. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM. Quality of life and Quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res. 1999;8(8):723–31.

    Article  PubMed  CAS  Google Scholar 

  18. Martin M, Lluch A, Segui M, Anton A, Fernandez-Chacon C, et al. Toxicity and health-related quality of life in node-negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. J Clin Oncol. 2005;23(16s):604.

    Google Scholar 

  19. Schnipper HH. Life after breast cancer. J Clin Oncol. 2001;19(15):3581–4.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Authors would like to thank all the patients who participated in our study and all the staff of Radiotherapy center in Namazi hospital, Shiraz, Iran. Some part of this study was funded by Shiraz University of Medical Sciences.

Author information

Authors and Affiliations

  1. Department of Health Service Management, Iran University of Medical Sciences, 1968643513, Tehran, Iran

    Peivand Bastani

  2. Division of Health Economics, Centre for Primary Health Care Research, Lund University, Malmö University Hospital, Clinical Research Center, Entrance 72, House 28, 20502, Malmö, Sweden

    Aliasghar Ahmad Kiadaliri

  3. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, 14155, Tehran, Iran

    Aliasghar Ahmad Kiadaliri

Authors
  1. Peivand Bastani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aliasghar Ahmad Kiadaliri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aliasghar Ahmad Kiadaliri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bastani, P., Ahmad Kiadaliri, A. Health-related quality of life after chemotherapy cycle in breast cancer in Iran. Med Oncol 28 (Suppl 1), 70–74 (2011). https://doi.org/10.1007/s12032-010-9714-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9714-x

Keywords

Search

Navigation